We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Outcome Measures in Duchenne Muscular Dystrophy: A Natural History Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02780492
Recruitment Status : Recruiting
First Posted : May 23, 2016
Last Update Posted : May 24, 2016
Sponsor:
Collaborators:
Association Française contre les Myopathies (AFM), Paris
University of Newcastle Upon-Tyne
Groupe Hospitalier Pitie-Salpetriere
Leiden University Medical Center
Radboud University
Information provided by (Responsible Party):
University College, London

May 19, 2016
May 23, 2016
May 24, 2016
June 2012
December 2019   (Final data collection date for primary outcome measure)
Disease progression [ Time Frame: up to 4 years ]
Evaluate disease progression from ambulant to non-ambulant patients through a composite assessment tool
Same as current
Complete list of historical versions of study NCT02780492 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Outcome Measures in Duchenne Muscular Dystrophy: A Natural History Study
Developing Tools for Assessing the Natural History of Ambulant and Non-ambulant DMD Individuals to Assist in Antisense-oligomer Clinical Trials
Novel emerging therapies for Duchenne Muscular Dystrophy (DMD) require a deeper understanding of DMD natural history. This study aim to assess the natural history of DMD through a composite assessment tool capable of capturing disease progression linking ambulant and non-ambulant phases of the disease.

Novel emerging therapies for Duchenne Muscular Dystrophy (DMD) require a deeper understanding of DMD natural history. This study aim to assess the natural history of DMD through a composite assessment tool capable of capturing disease progression linking ambulant and non-ambulant phases of the disease.

With a recruitment target of 80 DMD patients across 5 centres (London, Newcastle, Paris, Leiden, Nijmegen), subjects are assessed 6 monthly according to a shared protocol. Assessments include 6-minute walk distance (6MWD), North Star Ambulatory Assessment (NSAA), Performance of Upper Limb (PUL) and MyoSet (myogrip, myopinch and moviplate). Both ambulant and non-ambulant subjects undergo upper limb evaluation and respiratory function test including forced vital capacity (FVC), maximum inspiratory and expiratory pressures (MIP/MEP). A subgroup of patients performs annual whole body DEXA scan. An imaging sub-study will aim to characterize muscle (upper/lower limb) and brain MRI.

The investigators will analyze the longitudinal data for the different assessment tools and explore correlations among them.

This study will offer a comprehensive natural history of DMD including novel outcome measures, allowing to capture disease progression and explore the relationship between different assessment tools.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
80 patients with Duchenne muscular dystrophy (DMD) recruited across 5 specialised neuromuscular centres (London, Newcastle, Paris, Leiden, Nijmegen)
Duchenne Muscular Dystrophy
Other: Set of assessment tools
  • Ambulant patients
    A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
    Intervention: Other: Set of assessment tools
  • Non-ambulant patients
    A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
    Intervention: Other: Set of assessment tools
  • Healthy volunteers and Disease controls
    A set of assessment tools (upper limb function tests, MRI, blood analyses) will be performed
    Intervention: Other: Set of assessment tools
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
December 2019
December 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

For non-ambulant patients:

  1. Children and teenagers aged between 5 and 18 years with DMD, who have lost the ability to walk 10 meters with no support
  2. The diagnosis of DMD must be documented by genetic testing. If a muscle biopsy is available, it should contain less than 10% of revertant fibres
  3. Patients should have deletions amenable of skipping of exons 51 or 53 or 45 or 44 or 46 or 50 or 52
  4. Patients should be capable of sitting upright in a wheelchair for at least an hour
  5. Patients should be stable from a respiratory point of view. Artificial ventilation with either Bipap or tracheostomy is not a contraindication to the study.
  6. Informed consent signed by a parent/legal guardian (or by the patient if 16 years of age).
  7. In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.

For ambulant patients:

  1. Ambulant children from 5 years old and teenagers with DMD, and potential candidates for future genetic therapies with antisense oligomer (AO) exon skipping
  2. The diagnosis of DMD must be documented by MLPA or a standard genetic test for the disorder, genotypically confirmed to have an out-of-frame deletion(s) that could be corrected by skipping exon 51 or 53 or 45 or 44 or 46 or 50 or 52
  3. If a muscle biopsy is available less than 10% revertant fibres
  4. Ability to walk independently for at least 75 meters in 6 minutes at recruitment.
  5. Patients should receive the standard of care for DMD as recommended by the NorthStar UK and TREAT-NMD (i.e.: on glucocorticoids treatment)
  6. Sufficiently preserved pulmonary function (FVC >30%) and absence of symptoms of cardiac failure
  7. Informed consent signed by a parent/legal guardian (or by the patient if 16 years of age)
  8. In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.

For healthy volunteers and disease controls:

  1. Participant are able to provide informed consent/assent for taking blood samples and/or performing limb MRI and/or physiotherapy assessment of the upper limb function
  2. Participants have a neuromuscular disease that is not Duchenne Muscular Dystrophy or are a healthy volunteer with no neuromuscular disease
  3. Able to have a blood sample taken

Exclusion Criteria:

For non-ambulant patients:

  1. Patients who are currently involved in interventional clinical trials aimed at restoring dystrophin will be excluded, as their data could not be used to establish natural history of the disease (participation in a previous interventional clinical trial prior to 6 months from being recruited in the study is not an exclusion criterion)
  2. Patients with severe intellectual impairment, who would be unable to cooperate with examination
  3. Patients/families the investigators anticipate may have emotional/ psychological problems if recruited into a natural history study
  4. Symptomatic cardiac failure
  5. Recent (< 6 months) upper limb surgery or trauma
  6. Anticipated surgery for anytime during the duration of the study
  7. None of the current treatments for DMD are exclusion criteria
  8. For the MRI sub-study, patients with metal/metallic surgically inserted equipment incompatible with MRI scan will be excluded as well as patients suffering from claustrophobia.

For ambulant patients:

  1. Patients who are currently involved in interventional clinical trials aimed at restoring dystrophin will be excluded, as their data could not be used to establish natural history of the disease (participation in a previous interventional clinical trial prior to 6 months from being recruited in the study is not an exclusion criterion)
  2. Patients with severe intellectual impairment, who would be unable to cooperate with examination
  3. Patients/families the investigators anticipate may have emotional/ psychological problems if recruited into a natural history study
  4. Recent surgery or anticipated for anytime during the duration of the study
  5. For the MRI sub-study, patients with metal/metallic surgically inserted equipment incompatible with MRI scan will be excluded as well as patients suffering from claustrophobia.

For healthy volunteers and disease controls

  1. Patients who are currently involved in interventional clinical trials aimed at restoring dystrophin will be excluded, as their data could not be used to establish natural history of the disease (participation in a previous interventional clinical trial prior to 6 months from being recruited in the study is not an exclusion criterion)
  2. Patients with severe intellectual impairment, who would be unable to cooperate with examination
  3. Patients/families the investigators anticipate may have emotional/ psychological problems if recruited into a natural history study
  4. For the MRI sub-study, patients with metal/metallic surgically inserted equipment incompatible with MRI scan will be excluded as well as patients suffering from claustrophobia
Sexes Eligible for Study: Male
5 Years to 18 Years   (Child, Adult)
Yes
Contact: Dubowitz Neuromuscular Centre Institute of Child Health 02079052639
France,   Netherlands,   United Kingdom
 
 
NCT02780492
12/0096 (09DN17)
No
Not Provided
Plan to Share IPD: Yes
University College, London
University College, London
  • Association Française contre les Myopathies (AFM), Paris
  • University of Newcastle Upon-Tyne
  • Groupe Hospitalier Pitie-Salpetriere
  • Leiden University Medical Center
  • Radboud University
Principal Investigator: Francesco Muntoni, PhD Dubowitz Neuromuscular Centre, UCL-Institute of Child Health
University College, London
April 2016